Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias

Journal of Cardiovascular Electrophysiology

Volumn 11, Issue 6, 2000, Pages 691-696

  Napolitano, Carlo ^a,b   Schwartz, Peter J ^c   Brown, Arthur M ^d   Ronchetti, Elena ^a   Bianchi, Laura ^d   Pinnavaia, Aldo ^e   Acquaro, Giovanni ^e   Priori, Silvia G ^a  

^a IRCCS   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e Ospedale di Ivrea   (Italy)

Author keywords

Acquired long QT syndrome; Drug induced arrhythmias; Genetics; Sudden cardiac death

Indexed keywords

ANTIHISTAMINIC AGENT; CISAPRIDE; ION CHANNEL; KETOCONAZOLE;

ADULT; ARTICLE; CASE REPORT; DNA SEQUENCE; DRUG INDUCED DISEASE; ELECTROCARDIOGRAM; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENETIC RISK; HEART ARRHYTHMIA; HEART DEATH; HEART VENTRICLE FIBRILLATION; HUMAN; HYPOTHESIS; LONG QT SYNDROME; NUCLEOTIDE SEQUENCE; OOCYTE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SUDDEN DEATH; TORSADE DES POINTES; VOLTAGE CLAMP; XENOPUS;

EID: 0034083759     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2000.tb00033.x     Document Type: Article

References (42)

1. 1. Roden DM: A practical approach to torsade de pointes. Clin Cardiol 1997;20:285-290.
2. 2. Rosen MR: Of oocytes and runny noses. Circulation 1996;94:607-609.
3. 3. Priori SG, Diehl L, Schwartz PJ: Torsade de pointes. In Podrid PJ, Kowey PR, eds: Cardiac Arrhythmia. Mechanisms, Diagnosis and Management. Williams & Wilkins, Baltimore, 1995, pp. 951-963.
4. 4. Makkar RR, Fromm BS, Steinman RT, et al: Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270:2590-2597.
5. 5. Roden DM: Taking the "idio" out of "idiosyncratic": Predicting torsades de pointes. PACE 1998;21:1029-1034.
6. 6. Drici MD, Knollmann BC, Wang WX, Woosley RL: Cardiac actions of erythromycin: Influence of female sex. JAMA 1998; 280:1774-1776.
7. 7. Hii JT, Wyse DG, Gillis AM, Duff HJ, Solylo MA, Mitchell LB: Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation 1992;86:1376-1382.
8. 8. Moss AJ, Schwartz PJ: Delayed repolarization (QT or QTU prolongation) and malignant ventricular arrhythmias. Mod Concepts Cardiovasc Dis 1982:51:85-90.
9. 9. Schwartz PJ, Priori SG, Napolitano C. The long QT syndrome. In Zipes DP, Jalife J, eds: Cardiac Electrophysiology: From Cell to Bedside. Second Edition. WB Saunders, Philadelphia, 2000, pp. 597-615.
10. 10. Schwartz PJ: Idiopathic long QT syndrome: Progress and questions. Am Heart J 1985;109:399-411.
11. 11. Curran ME, Splawski I, Timothy KW, et al: A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995;80:795-803.
12. 12. Priori SG, Napolitano C, Schwartz PJ: Low penetrance in the long QT syndrome. Clinical impact. Circulation 1999;99:529-533.
13. 13. Vincent GM, Timothy KW, Leppert M, et al: The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Engl J Med 1992;327:846-852.
14. 14. Priori SG, Napolitano C, Schwartz PJ, et al: KvLQT1 mutation in drug induced torsade de pointes. (Abstract) Eur Heart J 1997; 18(Suppl):29.
15. 15. Schulze-Bahr E, Haverkamp W, Hordt M, et al: Do mutations in cardiac ion channel genes predispose to drug-induced (acquired) long QT syndrome? (Abstract) Circulation 1997;96(Suppl 1):211.
16. 16. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
17. 17. Splawski I, Shen J, Timothy KW, et al: Genomic structure of three long QT syndrome genes: KvLQT1, HERG, and KCNEI. Genomics 1998;51:88-97.
18. 18. Wang Q, Zhizhung L, Jiaxiang S, et al: Genomic organization of the human SCN5A gene encoding the cardiac sodium channel. Genomics 1996;34:9-16.
19. 19. Orita M, Iwahana H, Kanazawa H, et al: Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci U S A 1989;86: 2766-2770.
20. 20. Rampe D, Roy ML, Dennis A, Brown AM: A mechanism for the proarrhythmic effects of cisapride (Propulsid): High affinity blockade of the human cardiac potassium channel HERG. FEBS Lett 1997;417:28-32.
21. 21. Roy ML, Dumaine R, Brown AM: HERG, a primary human ventricular target of nonsedating antihistamine terfenadine. Circulation 1996;94:817-823.
22. 22. Antzelevitch C, Sun ZQ, Zhang ZQ, et al: Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol 1996;28:1836-1848.
23. 23. Priori SG: Exploring the hidden danger of non cardiac drugs. J Cardiovasc Electrophysiol 1998;9:1-3.
24. 24. Woosley RL: Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol 1996;36:233-252.
25. 25. Ahmad SR, Wolfe SM: Cisapride and torsades de pointes. (Letter) Lancet 1995;345:508.
26. 26. Wiseman LR, Faulds D: Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994;47:116-152.
27. 27. Vitola J, Vukanovic J, Roden DM: Cisapride-induced torsades de pointes. J Cardiovasc Electrophysiol 1998;9:1109-1113.
28. 28. Olsson S, Edwards IR: Tachycardia during cisapride treatment. Br Med J 1992;26;748-749.
29. 29. Pratt CM, Hertz RP, Ellis BE, et al: Risk of developing life-threatening ventricular arrhythmia associated with terfenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine. Am J Cardiol 1994;73:346-352.
30. 30. Jurima-Romet M, Crawford K, Cyr T, et al: Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 1994;22:849-857.
31. 31. Gray VS: Syncopal episodes associated with cisapride and concurrent drugs. Ann Pharmacother 1998;32:648-651.
32. 32. Salerno DM, Katz A, Dunbar DN, et al: Serum electrolytes and catecholamines after cardioversion from ventricular tachycardia and atrial fibrillation. PACE 1993;16:1862-1871.
33. 33. Puisieux FL, Adamantidis MM, Dumotier BM, et al: Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres. Br J Pharmacol 1996;117: 1377-1379.
34. 34. Wang Q, Curran ME, Splawski I, et al: Positional cloning of a novel potassium channel gene: KvLQT1 mutations cause cardiac arrhythmias. Nat Genet 1996;12:17-23.
35. 35. Wilson R, Ainscough R, Anderson K, et al: 2.2 Mb of contiguous nucleotide sequence from chromosome III of C. elegans. Nature 1994;368:32-38.
36. + conduction and selectivity. Science 1998;280:69-77.
37. 37. Donger C, Denjoy I, Berthet M, et al: KvLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation 1997;96:2778-2781.
38. 38. Schwartz PJ: The Long QT Syndrome. In Camm AJ, ed: Clinical Approaches to Tachyarrhythmias Series. Futura Publishing Co., Armonk, NY, 1997.
39. 39. Priori SG, Napolitano C, Brown AM, et al: The loss of function induced by HERG and KvLQT1 mutations does not correlate with the clinical phenotype. (Abstract) Circulation 1998;98(Suppl 1):1-457.
40. 40. Abbott GW, Sesti F, Splawski I, et al: MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999;97:175-187.
41. 41. Wei J, Abbott GW, Sesti F, et al: Prevalence of KCNE2 (Mirp1) mutations in acquired long QT syndrome. (Abstract) Circulation 1999;100:1-495.
42. 42. Wei J, Yang ICH, Tapper AR, et al: KCNE1 polymorphism confers risk of drug-induced long QT syndrome by altering kinetic properties of IKs potassium current. (Abstract) Circulation 1999; 100:1-495.